Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Q3 2026 › vs Q2 2026
Tonix Pharmaceuticals Holding (TNXP) Q3 2026 vs Q2 2026 (quarter over quarter)
Tonix Pharmaceuticals Holding's revenue rose $3.7M (+27%) from $13.5M in Q2 2026 to $17.2M in Q3 2026. The biggest changes: Tonmya +$4.1M (+37%); Zembrace Symtouch −$475K (-24%); Tosymra +$95K (+16%).
Tonix Pharmaceuticals Holding, Q3 2026: revenue $17.2M (+424% year over year), operating margin -321.6%, net loss $53.3M, operating cash flow −$41.1M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Tonmya | $15.0M | $11.0M | $4.1M | +37% |
| Zembrace Symtouch | $1.5M | $2.0M | −$475K | -24% |
| Tosymra | $689K | $594K | $95K | +16% |
| Revenue | $17.2M | $13.5M | $3.7M | +27% |
| Other income, net | $2.1M | $2.0M | $120K | +6% |
| Net loss | $53.3M | $40.6M | $12.8M | +32% |
| Costs & expenses | $72.7M | $56.1M | $16.6M | +30% |
| Operating costs | $72.7M | $56.1M | $16.6M | +30% |
| Cost of revenue | $1.3M | $703K | $549K | +78% |
| Research & development | $25.8M | $19.4M | $6.4M | +33% |
| SG&A | $45.6M | $36.0M | $9.6M | +27% |
| Operating cash sources | $53.3M | $40.6M | $12.8M | +32% |
| Depreciation & amortization | $643K | $619K | $24K | +4% |
| Share-based compensation | $2.3M | $2.3M | $37K | +2% |
| Working capital & other | $9.3M | −$4.6M | $13.9M | — |
| Cash used in operations | $41.1M | $42.2M | −$1.2M | -3% |
| Net loss absorbed | $53.3M | $40.6M | $12.8M | +32% |
Questions
How much did Tonix Pharmaceuticals Holding's revenue grow quarter over quarter in Q3 2026?
Tonix Pharmaceuticals Holding's revenue rose $3.7M (+27%) from $13.5M in Q2 2026 to $17.2M in Q3 2026.
What drove Tonix Pharmaceuticals Holding's revenue change in Q3 2026?
Tonmya +$4.1M (+37%); Zembrace Symtouch −$475K (-24%); Tosymra +$95K (+16%).